“fasciotens is a novel technology and has the potential to aid earlier closure of open abdominal wounds, reduce pain and reduce the length of hospital stay”
NICE recently published a Medtech innovation briefing (MIB) on using fasciotens products for abdominal wall closure. The briefing highlights the potential benefits of using fasciotens for complex hernias and open abdomen treatments.
Experts involved in the MIB noted that fasciotens has thepotential to aid earlier closure of open abdominal wounds which could lead to shorter hospital stays.
This could have significant implications for healthcare providers and patients alike, particularly in terms of reducing healthcare costs and improving patient outcomes.
“We are pleased to see the NICE Institute’s evaluation of fasciotens devices, and we believe that this MIB will provide decision-makers in the NHS, as well as 
surgeons and purchasers, with a decision guidance for these innovative and new medical products.,” said Clemens Winkler, Head of medical and science affairs at fasciotens.
The MIB on fasciotens products is now available on the NICE Institute’s website and can be accessed with the codeMIB321.
For more information about fasciotens and its potential benefits in abdominal wall surgery, please visit the company’s website at www.fasciotens.com and reach out to the UK distribution partner ProSys.
